Composite
68%
Novelty
68%
Feasibility
70%
Impact
65%
Mechanistic
60%
Druggability
75%
Safety
55%
Confidence
62%

Mechanistic description

Astrocyte-produced PGE2 (via COX2 induction) engages microglial EP2 receptors, elevating cAMP and activating PKA. PKA phosphorylates NF-κB p65(S276), altering transcriptional kinetics. Simultaneously, PKA activates SIRT1, which deacetylates H4K16 at trained enhancers, destabilizing the epigenetic memory complex (BET proteins + BRD4). Strong pharmacological tractability due to existing EP2 agonists.

Evidence for (8)

  • PGE2-EP2 signaling suppresses microglial inflammation via cAMP/PKA

  • SIRT1 activation resets trained immunity in macrophages

  • EP2 receptor modulation reduces neuroinflammation in Alzheimer's models

  • Restoring metabolism of myeloid cells reverses cognitive decline in ageing.

    PMID:33473210 2021 Nature
  • Cyclooxygenase-1 deletion in 5 × FAD mice protects against microglia-induced neuroinflammation and mitigates cognitive impairment.

    PMID:40847374 2025 Transl Neurodegener
  • EP2 Receptor Signaling Regulates Microglia Death.

    PMID:25715797 2015 Mol Pharmacol
  • Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia.

    PMID:24089506 2013 J Neurosci
  • Novel Microglia Cell Line Expressing the Human EP2 Receptor.

    PMID:31469538 2019 ACS Chem Neurosci

Evidence against (2)

  • PGE2 signaling has complex, often pro-inflammatory roles depending on receptor subtype (EP2 vs EP4)

  • Systemic COX2 inhibition associated with cardiovascular risks limits therapeutic window

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.